TFX
Teleflex Incorporated124.87
-1.85-1.46%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Details buybacks, smooth integration.
Q&A pinned down divestiture proceeds use: $1B share repurchases, $800M debt paydown on revolver balances. Biotronik integration advances smoothly—salesforces merged, retention solid, synergies ahead—while R&D ramps in Interventional and Vascular beyond the acquisition. Surgical nuggets surfaced: ENT instruments and ligation drive growth, appliers eyed for EMEA upside; VBP comps ease in 2026. Tariffs add uncertainty, but guidance absorbs expected hits. Integration's on track. Management stayed coy on 2027 EPS yet nodded to models near $10 via leverage. Watch deal closes for buyback kickoff.
Key Stats
Market Cap
5.52BP/E (TTM)
-Basic EPS (TTM)
-7.17Dividend Yield
0.01%Recent Filings
10-K
FY2025 results
Teleflex's FY2025 continuing operations delivered $1.99B in revenue, up 17% y/y, powered by the Q3-acquired VI Business adding $202M while legacy lines grew via volume and new products. Q4 momentum shone in EMEA with 39% y/y revenue surge from VI integration and Italian payback reserve releases, though margins compressed 480bps to 56% from acquisition intangibles, tariffs, and inflation. Americas climbed 11% on existing product strength; operating profit dipped 4% amid $100M Titan SGS impairment and $137M restructuring hits. Debt hit $2.7B post-VI buy, yet cash flow covered ops; $2B Strategic Divestitures loom H2 2026. Divestitures pending. Strong competition threatens.
8-K
Restructuring eyes $48-52M savings
Teleflex's board approved a multi-year restructuring plan on February 23, 2026, tied to its Strategic Divestitures of Acute Care, Interventional Urology, and OEM units, eyeing $31-37 million in charges but $48-52 million annual pre-tax savings by mid-2028. Restructuring targets stranded costs via workforce cuts and asset rationalization, while 2026 guidance flags $90 million stranded costs yet mid-single-digit pro forma adjusted constant currency revenue growth. Charges hit mostly in 2026.
8-K
CEO separation finalized
Teleflex finalized its separation agreement with ex-CEO Liam Kelly on January 23, 2026, following his President and CEO departure on January 7 and board resignation. Kelly stays on payroll through March 31, 2026, for transition services, receiving base salary, benefits, and vesting equity. Severance mirrors his 2017 agreement. Leadership transition now locked in.
8-K
CEO ousted; revenue cut.
Teleflex ousted CEO Liam Kelly effective January 7, 2026, appointing board member Stuart Randle as interim CEO starting January 8 with a $140,000 monthly stipend and $1.5 million restricted stock grant. Board chair Dr. Stephen Klasko leads the Spencer Stuart search for a permanent successor amid announced divestitures. Preliminary 2025 revenue slashed to $3.270-$3.278 billion from $3.305-$3.320 billion due to weak intra-aortic balloon pump demand and OEM delays. Leadership shift tests execution.
8-K
Teleflex sells units for $2.03B
Teleflex signed deals on December 9, 2025, to sell its OEM business for $1.5B cash to a Montagu-Kohlberg affiliate and Acute Care plus Interventional Urology for $530M cash to Intersurgical. Closings eyed for H2 2026, pending approvals; net proceeds earmarked for $1B share repurchases and debt paydown. Deals sharpen focus on core segments. Regulatory hurdles loom.
IPO
Website
Employees
Sector
Industry
AVTR
Avantor, Inc.
11.20-0.08
BAX
Baxter International Inc.
19.05-0.48
BDX
Becton, Dickinson and Company
196.39-3.70
BSX
Boston Scientific Corporation
92.95+0.76
ICUI
ICU Medical, Inc.
147.07-0.96
LMAT
LeMaitre Vascular, Inc.
83.41+0.64
MBOT
Microbot Medical Inc.
2.22+0.01
MMSI
Merit Medical Systems, Inc.
86.85+0.44
SYK
Stryker Corporation
351.69-3.62
UTMD
Utah Medical Products, Inc.
58.43+0.94